Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : IMM-101,Gemcitabine,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Precision-Panc
Deal Size : Inapplicable
Deal Type : Inapplicable
Precision-Panc Launches PRIMUS-006 Study
Details : IMM-101, is a broad-spectrum immunomodulatory agent investigated in combination with gemcitabine and pembrolizumab as first-line treatment in patients with metastatic pancreatic cancer.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 18, 2024
Lead Product(s) : IMM-101,Gemcitabine,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Precision-Panc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IMM-101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 3 study approved by Health Canada seeks to boost cancer patients’ immune systems with IMM-101 to protect against severe COVID-19 and other viral lung infections.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 07, 2020
Lead Product(s) : IMM-101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Immodulon, Champalimaud Foundation Team Up on ‘Difficult To Treat’ Cancers
Details : Collaboration will explore clinical trials with IMM-101, in combination with other treatments, in difficult to treat cancers, with a particular focus on epithelial cancers such as pancreatic cancer and sarcoma.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 08, 2020
Lead Product(s) : IMM-101
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : Impatients N.V. trading as myTomorrows
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 24, 2019
Lead Product(s) : IMM-101
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Impatients N.V. trading as myTomorrows
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
October 18, 2018
Lead Product(s) : IMM-101
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 04, 2017
Lead Product(s) : IMM-101
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IMM-101
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 21, 2012
Lead Product(s) : IMM-101
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
February 28, 2012
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 04, 2011
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 24, 2011
Reset All
